Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537948 | 0.88 | ALDH1A1 (0.84) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL30610305 | 0.88 | ALDH1A1 (0.73) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL9976087 | 0.88 | ALDH1A1 (0.73) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL4026842 | 0.84 | ALDH1A1 (0.64) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL5347059 | 0.81 | ALDH1A1 (0.97) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL28137833 | 0.79 | ALDH1A1 (1.00) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL2360974 | 0.78 | ALDH1A1 (0.84) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL4032571 | 0.78 | PKM (0.55) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL7890976 | 0.76 | ALDH1A1 (0.57) | ALDH1A1PKMMEN1KMT2APOLB | |
| SCHEMBL29432508 | 0.74 | ALDH1A1 (0.73) | ALDH1A1PKMMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1244648-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORP (US) | 2009-04-15 | — | — | EP | disclosed |
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2007-03-15 | — | — | US | disclosed |
| US-7022717-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2006-04-04 | — | — | US | disclosed |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | BRIDGER GARY J | 2006-03-30 | — | — | US | disclosed |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2004-05-27 | — | — | US | disclosed |
| US-6667320-B2 | For therapy of infalmmation; asthma, cancer, arthritis, multiple sclerosis; prophylaxis of infection of target cells by a human immunodeficiency virus (HIV) | ANORMED (CA) | 2003-12-23 | — | — | US | disclosed |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | ANORMED CORPORATION (CA) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060591-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | ALDH1A1 3141/4885PKM 1780/4885MEN1 3670/4885 |
| US-20040102428-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | ALDH1A1 3141/4885PKM 1780/4885MEN1 3670/4885 |
| US-20020077339-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | ALDH1A1 3141/4885PKM 1780/4885MEN1 3670/4885 |
| US-20060069129-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, ACKR3, CCR2 | ALDH1A1 3141/4885PKM 1780/4885MEN1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.